舒利迭联合孟鲁司特治疗儿童支气管哮喘的疗效观察

Observation on the curative effect of seretide combined with montelukast in the treatment of bronchial asthma in children

目的:探讨舒利迭联合孟鲁司特治疗儿童支气管哮喘的疗效。方法:选择2016年1—12月我院收治的轻、中度支气管哮喘患儿104例,采用随机数字表分组原则将其分为对照组与研究组,每组各52例。对照组患儿应用舒利迭吸入治疗,其中12岁儿童每次剂量为50μg/250μg(50μg沙美特罗和250μg丙酸氟替卡松),每日2次;4~11岁儿童每次剂量为50μg/100μg(50μg沙美特罗和100μg丙酸氟替卡松),每日2次。研究组在此基础上联合孟鲁司特治疗,其中≤5岁患儿每次4 mg,每日1次;5岁以上患儿每次5 mg,每日1次。观察3个月,比较两组患儿的临床治疗效果与治疗前后肺功能指标的变化。结果:研究组治疗3个月后总有效率(96.1%)高于对照组(82.7%,P<0.05)。研究组治疗后肺功能指标第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰值流速(PEF)和FEV1占预计值百分比(FEV1%)均高于对照组(P<0.05)。结论:舒利迭联合孟鲁司特治疗轻中度儿童支气管哮喘的效果满意,适于临床应用。

Objective： To investigate the efficacy of seretide combined with montelukast in the treatment of bronchial asthma in children. Methods： One hundred and four children with mild or moderate bronchial asthma treated in the Out-patient Department of our hospital from Jan. to Dec. 2016 were randomly divided into control group and research group（52 each）. Children in control group received seretide inhalation therapy, those aged 12 years old were given a dose of 50 μg/250 μg（50 μg salmeterol and 250 μg fluticasone propionate）, twice a day; and those aged 4-11 years old were given a dose of 50 μg/100 μg（50 μg salmeterol and 100 μg fluticasone propionate）, twice a day. On this basis, children in research group received a combined montelukast therapy, those aged ≤ 5 years old were given a dose of 4 mg montelukast each time, once a day; and those aged ≥ 5 years old were given 5 mg montelukast, once a day. Three months after treatment, the clinical curative effect and the changes of lung function before and after treatment were compared between the two groups. Results： The total effective rate of research group was 96.1%, higher than that of control group（82.7%, P〈0.05）. The lung function indexes, forced expiratory volume in 1 second, forced vital capacity, peak expiratory flow, forced expiratory volume in 1 second as percentage of predicted volume in research group were higher than those in control group（P〈0.05）. Conclusions： Seretide combined with montelukast in the treatment of mild to moderate bronchial asthma in children shows satisfactory effect, and is suitable for clinical application.